No Data
No Data
MDNT Research Memo (10): Under the corporate vision 'VISION2030', we are proceeding with the development of a new medium-term management plan.
Progress of business activities and global strategy. Under the new management plan and corporate vision VISION2030, which will be launched in April 2022, Mr. Kubushiro took over as the new CEO from founder Mr. Kimura. The company is proceeding with the consideration of a new medium-term management plan that takes into account new perspectives and issues. Medinet <2370> announced "VISION2030" which outlines the company's desired state in 2030, with backcasting (from future to present).
MDNT Research Memo (9): The development policy for the treatment of chronic heart failure will be determined by the end of September 2024 based on the results of Phase IIb.
In the regenerative medicine product business, we are promoting two themes in product development: 1) Practical use of regenerative medicine products for the treatment of chronic heart failure (joint research and development with Kyushu University), and 2) Cultured cartilage using autologous cells for knee cartilage injuries.
MDNT Research Memo (8): Aim to establish ambidextrous management early and achieve profitability in the cell processing industry by September 2025 (2).
Increase the cell types and items of specific cell products manufactured under contract by pharmaceutical companies, universities, medical institutions, research institutions, etc. engaged in regenerative and cell therapy.
MDNT Research Memo (7): Aim to establish ambidextrous management early and achieve profitability in the cell processing industry by September 2025. (1)
Progress and growth strategy of Medinet's (2370) business activities: 1. Progress of cell processing business and future efforts. The cell processing business achieved profitability for the first time in the fiscal year ending September 2019, but due to the COVID-19 pandemic, patients receiving immune cell therapy (especially inbound patients) continued to refrain from visiting. In the fiscal year ending September 2023, as economic activity becomes more vigorous with the transition to COVID-19 infection control level 5 and immune cell therapy patients gradually return, the number of immune cell processing contracts is also on a recovery trend. The specific cell processing manufacturing industry is affected by the COVID-19 situation.
MDNT Research Memo (6): With abundant cash and deposits, the supply system for growth investment is solid.
Looking at the financial situation at the end of the second quarter of the September 2024 term, the total assets amounted to 61 billion yen (an increase of 466 million yen compared to the previous quarter).
MDNT Research Memo (5): Significant recovery in revenue for the second quarter ending September 2024.
Performance trend: 1. In the second quarter of the September 2024 fiscal year, the performance overview of Medinet <2370> was as follows: revenue was 3.99 billion yen (an increase of 14.4% compared to the same period last year), operating loss was 658 million yen (compared to a loss of 671 million yen in the same period last year), ordinary loss was 632 million yen (compared to a loss of 669 million yen in the same period last year), and quarterly net loss was 634 million yen (compared to a loss of 676 million yen in the same period last year). Gross profit on sales increased by 78 million yen (an increase of 15.2% compared to the same period last year) due to the increase in sales revenue, etc.
No Data